AzTrials
AzTrials

Depressive Disorder, MajorPhase 3NCT04442490

A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)

A Phase 3 study testing SAGE-217 in people with Depressive Disorder, Major, run by Biogen at 39 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study to evaluate the efficacy of SAGE-217 in the treatment of participants with MDD. Read more about this study

Who is it for?
Ages 18 to 64 years
Conditions the study is for
Depressive Disorder, Major
What is being tested?
SAGE-217
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
543 participants
Where
39 sitesUnited States
Study dates
12 May 2020to 21 Apr 2021
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 64 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Participant with diagnosis of MDD as diagnosed by Structured Clinical Interview for Diagnostic and Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Clinical Trial Version [SCID-5-CT], with symptoms that have been present for at least a 4-week period.
  • Participant has a Hamilton Rating Scale for Depression (HAM-D) total score ≥24 at screening and Day 1 (prior to dosing).
  • Participants taking antidepressants must have been taking these medications at the same dose for at least 60 days prior to Day 1. Participants who have stopped taking antidepressants within 60 days must have stopped for longer than 5 half-lives of the antidepressant prior to Day 1. Participants receiving psychotherapy must have been receiving therapy on a regular schedule for at least 60 days prior to Day 1.
  • Participant is willing to delay start of other antidepressant or antianxiety medications and any new pharmacotherapy regimens, including as-needed benzodiazepine anxiolytics and sleep aids, until after completion of the Day 42 visit.

Who cannot join

  • Participant is currently at significant risk of suicide, as judged by the Investigator, or has attempted suicide associated with the current episode of MDD.
  • Participant has onset of the current depressive episode during pregnancy or 4 weeks postpartum, or the participant has presented for screening during the 6-month postpartum period.
  • Participant has a body mass index (BMI) ≤18 or ≥45 kg/m^2 at Screening, which is subject to a broader evaluation of medical comorbidities.
  • Participant has treatment-resistant depression, defined as persistent depressive symptoms despite treatment with adequate doses of antidepressants within the current major depressive episode (excluding antipsychotics) from two different classes for at least 4 weeks of treatment.
  • Participant has a medical history of seizures, bipolar disorder, schizophrenia, and/or schizoaffective disorder.
  • Participant has a history of mild, moderate, or severe substance use disorder (including benzodiazepines) diagnosed using DSM-5 criteria in the 12 months prior to screening.
  • Participant is taking psychostimulants (eg, methylphenidate, amphetamine) or opioids, regularly or as-needed, at Day -28.

Trial locations and contacts

39 sites in 1 country.

39 sites in 1 country

United States39 sites
  • Sage Investigational Site

    Allentown, Pennsylvania, 18104

  • Sage Investigational Site

    Alpharetta, Georgia, 30022

  • Sage Investigational Site

    Atlanta, Georgia, 30328

  • Sage Investigational Site

    Atlanta, Georgia, 30331

  • Sage Investigational Site

    Bellflower, California, 90706

  • Sage Investigational Site

    Charleston, South Carolina, 29407

  • Sage Investigational Site

    Charlotte, North Carolina, 28211

  • Sage Investigational Site

    Charlottesville, Virginia, 22903

  • Sage Investigational Site

    Cincinnati, Ohio, 45215

  • Sage Investigational Site

    Coral Springs, Florida, 33067

  • Sage Investigational Site

    Dayton, Ohio, 45417

  • Sage Investigational Site

    Decatur, Georgia, 30030

  • Sage Investigational Site

    DeSoto, Texas, 75115

  • Sage Investigational Site

    Flowood, Mississippi, 39232

  • Sage Investigational Site

    Garden Grove, California, 92845

  • Sage Investigational Site

    Glendale, California, 91206

  • Sage Investigational Site

    Hollywood, Florida, 33024

  • Sage Investigational Site

    Jacksonville, Florida, 32256

  • Sage Investigational Site

    Las Vegas, Nevada, 89102

  • Sage Investigational Site

    Lauderhill, Florida, 33319

  • Sage Investigational Site

    Lemon Grove, California, 91945

  • Sage Investigational Site

    Marlton, New Jersey, 08053

  • Sage Investigational Site

    Memphis, Tennessee, 38119

  • Sage Investigational Site

    North Canton, Ohio, 44720

  • Sage Investigational Site

    O'Fallon, Missouri, 63368

  • Sage Investigational Site

    Oklahoma City, Oklahoma, 73112

  • Sage Investigational Site

    Orange, California, 92868

  • Sage Investigational Site

    Orange City, Florida, 32763

  • Sage Investigational Site

    Orlando, Florida, 32801

  • Sage Investigational Site

    Orlando, Florida, 32807

  • Sage Investigational Site

    Pico Rivera, California, 90660

  • Sage Investigational Site

    Portland, Oregon, 97210

  • Sage Investigational Site

    Redlands, California, 92374

  • Sage Investigational Site

    Rogers, Arkansas, 72758

  • Sage Investigational Site

    San Diego, California, 92103

  • Sage Investigational Site

    Sherman Oaks, California, 91403

  • Sage Investigational Site

    Skokie, Illinois, 60076

  • Sage Investigational Site

    Temecula, California, 92591

  • Sage Investigational Site

    Wichita Falls, Texas, 76309

Other trials in United States

About this study

Official title: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder

The purpose of this study to evaluate the efficacy of SAGE-217 in the treatment of participants with MDD.

Read the detailed description

This study was previously posted by Sage Therapeutics. In November 2023, sponsorship of the trial was transferred to Biogen.

Being tested
SAGE-217, Placebo
Keywords
Depression, Depressive disorder, SAGE-217
Medical subject headings
Depressive Disorder, Major, Depression, Depressive Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SAGE-217Drug

    SAGE-217 oral capsules.

  • PlaceboDrug

    SAGE-217 matched-placebo oral capsules.

Study groups in NCT04442490
Study groupRoleWhat they receive
PlaceboPlacebo comparatorParticipants self-administered SAGE-217 matched-placebo capsules, once daily at approximately 8 PM with fat-containing food for 14 days.
Receives: Drug: Placebo
SAGE-217 50 mgExperimentalParticipants self-administered SAGE-217 50 mg capsules, once daily at approximately 8 PM with fat-containing food for 14 days. Participants who could not tolerate 50 mg received 40 mg for the remainder of the treatment period as per discretion of investigator.
Receives: Drug: SAGE-217

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in the 17-item HAM-D Total Score at Day 15

    The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to the following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total HAM-D score is the sum of individual items, ranging from 0 to 52; where a higher score indicates more depression. A negative change indicates improvement. A mixed Model for Repeated Measures (MMRM)was used for the analysis.

    Measured: Baseline, Day 15

Secondary outcomes (10)
  1. Change From Baseline in the CGI-S Score at Day 15

    The CGI-S is a 7-point Likert scale to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participants who have the same diagnosis. A participant is assessed on severity of mental illness at the time of rating as 1=normal, not at all ill; 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7= among the most extremely ill participants. A negative change from baseline indicates improvement. MMRM was used for the analysis. A negative change from baseline indicates improvement. MMRM was used for the analysis.

    Measured: Baseline, Day 15

  2. Change From Baseline in the HAM-D Total Score at Days 3, 8 and 42

    The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to the following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total HAM-D score is the sum of individual items, ranging from 0 to 52; where a higher score indicates more depression. A negative change from baseline indicates improvement. MMRM was used for the analysis.

    Measured: Baseline, Days 3, 8, and 42

  3. Percentage of Participants Achieving HAM-D Response

    The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to the following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total HAM-D score is the sum of individual items, ranging from 0 to 52; where a higher score indicates more depression. HAM-D response is defined as having a greater than or equal to (≥) 50% reduction in HAM-D score from baseline. Generalized Estimating Equation (GEE) method was used for the analysis.

    Measured: Days 15 and 42

  4. Percentage of Participants Achieving HAM-D Remission

    The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to the following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total HAM-D score is the sum of individual items, ranging from 0 to 52; where a higher score indicates more depression. HAM-D remission is defined as HAM-D total score less than or equal to (≤) 7. GEE model was used for the analysis.

    Measured: Days 15 and 42

  5. Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response at Day 15

    CGI-I response is defined as having a CGI-I score of "very much improved" (score of 1) or "much improved" (score of 2)". The CGI-I employs a 7-point Likert scale to measure the overall improvement in the participant's condition posttreatment. Response choices include 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. GEE model was used for the analysis.

    Measured: Day 15

  6. Change From Baseline in MADRS Total Score at Day 15

    The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS total score was calculated as the sum of the 10 individual item scores and each item yields a score of 0 to 6. The overall MADRS score ranges from 0 to 60 where higher MADRS scores indicate more severe depression. A negative change indicates improvement. MMRM was used analysis.

    Measured: Baseline, Day 15

  7. Change From Baseline in HAM-A Total Score at Day 15

    The 14-item HAM-A is comprised of a series of symptoms, and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). The HAM-A total score was calculated as the sum of the 14 individual item scores. The scoring for HAM-A is calculated by assigning scores of 0 (not present) to 4 (very severe) to each item, with a total HAM-A score range of 0 to 56, where <17 indicates mild severity, 18 to 24 indicates mild to moderate severity, and 25 to 30 indicates moderate to severe severity. A negative change from baseline indicates improvement. MMRM was used for the analysis.

    Measured: Baseline, Day 15

  8. Time to First HAM-D Response

    17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. Total HAM-D score is sum of individual items, ranging from 0 to 52; where higher score indicates more depression. Time to first HAM-D response is defined as time from first administration of the study drug to first time when ≥50% reduction in HAM-D score from baseline is achieved.

    Measured: Up to Day 57

  9. Change From Baseline in Patient- Reported Outcome (PRO) Measures of Health-Related Quality of Life, as Assessed by the 36-item Short Form Version 2 (SF-36v2) Score at Days 8, 15, 28 and 42

    Participant's health was assessed using PRO health related quality of life (HRQOL) SF-36 V2. SF-36v2 covers 8 health dimensions, including 4 physical health status domains (physical functioning, role participation with physical health problems [role-physical], bodily pain, and general health) and 4 mental health status domains (vitality, social functioning, role participation with emotional health problems [role-emotional], and mental health). Physical Component Summary and the Mental Component Summary are derived from the 8 domains. Each domain is scored by summing the individual items, scores varying between 0 and 100. Both the domain scores and the component summary scores are norm-based. A higher score indicates a better state of health. Positive change indicates improvement. MMRM was used for the analysis.

    Measured: Baseline, Days 8, 15, 28 and 42

  10. Change From Baseline in PRO Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) Total Score at Days 8, 15, 28 and 42

    The PHQ-9 is a participant-rated depressive symptom severity scale where scoring is based on responses to specific questions. The score was calculated as the sum of the 9 individual item scores. The PHQ-9 total score ranges from 0 to 27 categorized as follows: 1 to 4 = minimal depression, 5 to 9 = mild depression, 10 to 14 = moderate depression, 15 to 19 = moderately severe depression, and 20 to 27 = severe depression with a higher score indicating more depression. A negative change indicates improvements. MMRM was used for analysis.

    Measured: Baseline, Days 8, 15, 28 and 42

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Jun 2020
  2. Study start12 May 2020
  3. Primary completion26 Mar 2021
  4. Study completion21 Apr 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
543 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04442490
Sponsor's protocol ID
217-MDD-301B
Status last verified
Dec 2023
First submitted
18 Jun 2020
Last updated
22 Dec 2023
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing SAGE-217 in people with Depressive Disorder, Major, run by Biogen at 39 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 39 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 5 Dec 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in the 17-item HAM-D Total Score at Day 15 (time frame: Baseline, Day 15). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Dec 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in